AIMS: Despite optimal oral anticoagulation with vitamin K antagonist, left atrial (LA) thrombus could be detected in the left appendage (LAA) in >2% of patients with atrial fibrillation (AF) and CHA2DS2-VASc score≥1 but few data are available for patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). We evaluated the occurrence and predictors of LA thrombi by means of transesophageal echocardiography (TOE) in consecutive patients with non-valvular AF who received for at least 3weeks Apixaban, Dabigatran, or Rivaroxaban. METHODS: This study included 414 consecutive patients (male 252, 60.6%, mean age 67.3years) referred to our Centers for catheter ablation of AF (n=220, 53.1%) or scheduled electrical cardioversion (n=194, 46.9%). Patients were on Dabigatran (n=160), Rivaroxaban (n=150) or Apixaban (n=104). TOE was performed in all cases within 12h prior to ablation or cardioversion. RESULTS: Preprocedural TOE revealed LA thrombus in 15/414 patients (3.6%), all located in the LAA (Apixaban 3/104 2.9%, Dabigatran 5/160 3.1%, and Rivaroxaban 7/150 4.7%, p=0.69). Of these, 14 patients had persistent AF. Patients with LAA thrombus had a mean CHA2DS2-VASc score of 3 (3-4). Higher CHA2DS2-VASc score (p=0.02), but not the type of NOAC, significantly predicted the presence of LA thrombus. CONCLUSION: The incidence of LAA thrombus in a cohort of patients anticoagulated with NOACs is low but not negligible, in any case similar among the 3 drugs. Preprocedural TOE should be considered in patients with a CHA2DS2-VASc score>3.
AIMS: Despite optimal oral anticoagulation with vitamin K antagonist, left atrial (LA) thrombus could be detected in the left appendage (LAA) in >2% of patients with atrial fibrillation (AF) and CHA2DS2-VASc score≥1 but few data are available for patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). We evaluated the occurrence and predictors of LA thrombi by means of transesophageal echocardiography (TOE) in consecutive patients with non-valvular AF who received for at least 3weeks Apixaban, Dabigatran, or Rivaroxaban. METHODS: This study included 414 consecutive patients (male 252, 60.6%, mean age 67.3years) referred to our Centers for catheter ablation of AF (n=220, 53.1%) or scheduled electrical cardioversion (n=194, 46.9%). Patients were on Dabigatran (n=160), Rivaroxaban (n=150) or Apixaban (n=104). TOE was performed in all cases within 12h prior to ablation or cardioversion. RESULTS: Preprocedural TOE revealed LA thrombus in 15/414 patients (3.6%), all located in the LAA (Apixaban 3/104 2.9%, Dabigatran 5/160 3.1%, and Rivaroxaban 7/150 4.7%, p=0.69). Of these, 14 patients had persistent AF. Patients with LAA thrombus had a mean CHA2DS2-VASc score of 3 (3-4). Higher CHA2DS2-VASc score (p=0.02), but not the type of NOAC, significantly predicted the presence of LA thrombus. CONCLUSION: The incidence of LAA thrombus in a cohort of patients anticoagulated with NOACs is low but not negligible, in any case similar among the 3 drugs. Preprocedural TOE should be considered in patients with a CHA2DS2-VASc score>3.
Authors: Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Antonio D'Onofrio; Paolo Golino; Gerardo Nigro Journal: J Thromb Thrombolysis Date: 2018-02 Impact factor: 2.300
Authors: Beata Uziębło-Życzkowska; Paweł Krzesiński; Agnieszka Jurek; Monika Budnik; Iwona Gorczyca; Agnieszka Kapłon-Cieślicka; Marek Kiliszek; Agnieszka Wójcik; Monika Gawałko; Olga Jelonek; Anna Michalska; Katarzyna Starzyk; Piotr Scisło; Janusz Kochanowski; Krzysztof J Filipiak; Beata Wożakowska-Kapłon; Grzegorz Opolski; Grzegorz Gielerak Journal: Cardiovasc Diagn Ther Date: 2020-08
Authors: Anna Rago; Andrea Antonio Papa; Giulia Arena; Marco Mosella; Antonio Cassese; Alberto Palladino; Paolo Golino Journal: Acta Myol Date: 2017-12-01
Authors: Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip Journal: Nat Rev Cardiol Date: 2020-10-27 Impact factor: 32.419
Authors: Sebastian Feickert; Giuseppe D Ancona; Hüseyin Ince; Kristof Graf; Elias Kugel; Monica Murero; Erdal Safak Journal: J Atr Fibrillation Date: 2020-10-31
Authors: Luis Marroquin; Gabriela Tirado-Conte; Radosław Pracoń; Witold Streb; Hipolito Gutierrez; Giacomo Boccuzzi; Dabit Arzamendi-Aizpurua; Ignacio Cruz-González; Juan Miguel Ruiz-Nodar; Jung-Sun Kim; Xavier Freixa; Jose Ramon Lopez-Minguez; Ole De Backer; Rafael Ruiz-Salmeron; Antonio Dominguez; Angela McInerney; Vicente Peral; Rodrigo Estevez-Loureiro; Eduard Fernandez-Nofrerias; Afonso B Freitas-Ferraz; Francesco Saia; Zenon Huczek; Livia Gheorghe; Pablo Salinas; Marcin Demkow; Jose R Delgado-Arana; Estefania Fernandez Peregrina; Zbibniew Kalarus; Ana Elvira Laffond; Yangsoo Jang; Jose Carlos Fernandez Camacho; Oh-Hyun Lee; Jose M Hernández-Garcia; Caterina Mas-Llado; Berenice Caneiro Queija; Ignacio J Amat-Santos; Maciej Dabrowski; Josep Rodés-Cabau; Luis Nombela Franco Journal: Heart Date: 2022-06-24 Impact factor: 7.365
Authors: Anna Michalska; Iwona Gorczyca; Magdalena Chrapek; Agnieszka Kapłon-Cieślicka; Beata Uziębło-Życzkowska; Katarzyna Starzyk; Olga Jelonek; Monika Budnik; Monika Gawałko; Paweł Krzesiński; Agnieszka Jurek; Piotr Scisło; Janusz Kochanowski; Marek Kiliszek; Grzegorz Gielerak; Krzysztof J Filipiak; Grzegorz Opolski; Beata Wożakowska-Kapłon Journal: Medicine (Baltimore) Date: 2020-06-19 Impact factor: 1.817